Kineta Inc.

Please note: The information displayed on this page might be outdated.
Kineta Inc.: Kineta (Private) expertise in innate immunity and immunology. Wholly owned preclinical human anti-VISTA antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. VISTA is the most highly expressed checkpoint in hard to treat tumors. $360M+ deal with Genentech for KCP506 non-opioid for chronic pain, a first in class a9/a10 Nicotinic Acetylcholine Receptor (nAChR) antagonist - initiated Ph1 4Q2020. LHF-535 for the treatment of Lassa Fever wholly funded by Wellcome Trust (priority review voucher upon approval, Ph2/3 start in 2021).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Anti-infectives, Antivirals, Autoimmune, Dermatology, Immuno-Oncology, Immunotherapy, Infectious Disease, Ophthalmology, Pain
Finance
Pre-Revenues
Industry
Biotechnology
Investement Strategy
Under the Radar
Listing
Private
Market Cap
Private
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
219 Terry Ave N.
Suite 300
Seattle, WA 98109
United States

Company Participants at Hamptons CEO Roundtable 2019

  • Shawn Iadonato, PhD, CEO/Co-Founder